A Study of LY4213663
Phase 1
134
about 2.3 years
18–75
9 sites in AL, AZ, FL +1
What this study is about
Researchers are testing a treatment called LY4213663 in people who are healthy and those with rheumatoid arthritis (RA). The trial will last about 33 weeks, excluding the time needed to be screened for eligibility. Blood tests will be done to see how well the body processes the drug and what effects it has.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take LY4213663
- 2.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Secondary: PK: Area Under the Concentration Versus Time Curve (AUC) of LY4213663, Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY4213663
Immune